ACR 246
Alternative Names: ACR-246Latest Information Update: 06 Jul 2026
At a glance
- Originator Hangzhou Adcoris Biopharmacy
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Squamous cell cancer
Most Recent Events
- 22 Apr 2026 Efficacy and adverse events data from a phase I/II trial in solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 17 Oct 2025 Preclinical trials in Squamous cell cancer in China (IV), prior to October 2025
- 17 Oct 2025 Pharmacodynamics data from preclinical trials in Squamous cell cancer presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)